5 results about "Sialic acid binding" patented technology

This invention discloses a sialyl polysaccharide-sialic acid-binding immunoglobulin-like lectin signaling pathway blocker, containing one or more N-acetylneuraminic acid derivatives, used to manufacture immunotherapy synergistic drugs or immunomodulatory drugs. The immunotherapy synergistic drugs are used in combination with immunotherapy drugs, and the immunomodulatory drugs are used to enhance the regulation of immunity.

This invention discloses a method for preparing a fusion protein of sialic acid-binding immunoglobulin-like lectin 6 extracellular fragment and human immunoglobulin G1-Fc fragment, and its application, belonging to the field of biomedical technology. The fusion protein consists of a functional fragment of the Siglec-6 extracellular region linked to the Fc fragment of human IgG1 via a peptide linker. Its amino acid sequence is selected from one of SEQ ID No. 1, SEQ ID No. 2, or SEQ ID No. 3, or a variant with more than 90% homology to the above sequences and retaining the biological activity of Siglec-6. The preparation method includes: cloning the Siglec-6 fragment and the coding sequence of the Fc fragment, constructing a recombinant expression plasmid and transfecting it into mammalian cells to induce expression, and purifying the target protein by affinity chromatography. The fusion protein vcSig6-Fc of this invention has extremely high structural stability and ligand binding affinity, can significantly inhibit the expression of inflammatory factors and matrix-degrading enzymes in chondrocytes, and shows excellent performance in promoting COL2A1 expression, thus exhibiting good protective effects on articular cartilage and therapeutic effects on rheumatoid arthritis.

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such as the spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-S with high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and / or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

The application designs a method for in situ engineering of immune T cells by chemical means, and selects 4-(hydrazinocarbonyl) phenylboronic acid (PBA-Hz) as an immune cell engineering tool. Galactose oxidase (GAO) is used to oxidize the galactose and acetylgalactosamine at the end of the sugar chain on the surface of immune T cells to generate aldehyde groups, which are covalently connected with the hydrazine of PBA-Hz, and the engineered cell T PBA is obtained. PBA The phenylboronic acid on the surface of the cell can be specifically covalently combined with sialic acid on the tumor cell, so that the T PBA cell can better target the tumor cell for killing. At the same time, due to the blocking of the sialic acid site on the surface of the tumor cell, the sialic acid binding immunoglobulin-like lectin on the surface of the natural killer (NK) cell cannot bind to the sialic acid, thereby relieving the immune suppression on the NK cell. The application is a new type of engineered immune cell therapy, which has great application potential in cancer and other related diseases.

Technologies for the prevention and / or treatment of pathogenic or microbial infections. Compositions relate to compositions, vaccines and methods comprising an immunogenic multiple antigen presenting system (MAPS), where two or more biotinylated polysaccharide antigens are interconnected or joined together by one or more fusion proteins comprising (i) a sialic acid binding domain (SBD) and (ii) a biotin-binding moiety (BBM), thereby facilitating the joining multiple polysaccharide antigens together in the complex to form a cross-linked MAPS-X immunogenic complex. The polysaccharide antigens that are linked can be on the same polysaccharide macromolecule or on distinct polysaccharide macromolecules.